| Reference |
Clustering method |
Classification method |
Cancer |
Clinico-biological significance |
| Golub TR et al.,1999 [4] |
Self- organizing maps |
Linear discriminant analysis |
ALL vs. AML |
A distinction that is critical for successful treatment |
| Alizadeh AA et al., 2000 [5] |
clustering Hierarchical |
N/A |
DLBCL |
Subtypes with differences in the stages ofB-cell differentiation (germinal center,activated B-cell) and their relation withprognosis |
| Perou CM et al.,2000; Sorlie T etal., 2003; van 'tVeer LJ et al.,2002; van deVijver MJ, et al. 2009 [8,9] |
Hierarchical clustering |
Various: PAM,correlation withcategories |
Breastcancer |
Subtypes (basal, luminal A, luminal B,HER2+) with differences with regard toclinical features, response to treatment,and prognosis. |
| Salazar R et al.,2011 [12] |
|
A nearest meanclassifier |
CRC |
Classifier that can predict patients withearly-stage CRC |
Collisson EA et al.,
2011 [28] |
NMF |
N/A |
PDA |
Subtypes of PDA and their responses totherapy |
| Sadanandam A etal., 2013 [29] |
NMF |
PAM |
CRC |
Subtypes of CRC and their relation withcellular phenotype and response to therapy |
| Armstrong SA, etal, 2003 [40] |
N/A |
K-nearest-neighbors |
MLL |
Rearrangement of the MLL genedistinguishes a unique leukemia |
| Tan IB, et al 2011 [11] |
NMF |
SVM |
GC |
Subtypes of GC and their relation withsurvival and response to chemotherapy |
| Budinska et al,2013 [29] |
Hierarchicalclustering |
Multiclass LDA |
CRC |
Subtypes with molecular heterogeneity |
